Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans.

Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun MA, Sheline YI.

Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14968-73. doi: 10.1073/pnas.1107411108. Epub 2011 Aug 22.

2.

[Molecular imaging of beta-amyloid plaques in the brain].

Ono M.

Brain Nerve. 2007 Mar;59(3):233-40. Review. Japanese.

PMID:
17370649
3.

Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.

Vallabhajosula S.

Semin Nucl Med. 2011 Jul;41(4):283-99. doi: 10.1053/j.semnuclmed.2011.02.005. Review.

PMID:
21624562
4.

Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography.

Henriksen G, Yousefi BH, Drzezga A, Wester HJ.

Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S75-81. doi: 10.1007/s00259-007-0705-x. Review.

PMID:
18224319
5.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
6.

Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

Klein WL, Krafft GA, Finch CE.

Trends Neurosci. 2001 Apr;24(4):219-24. Review.

PMID:
11250006
7.

Impact of amyloid imaging on drug development in Alzheimer's disease.

Mathis CA, Lopresti BJ, Klunk WE.

Nucl Med Biol. 2007 Oct;34(7):809-22. Epub 2007 Sep 4. Review.

8.

Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease.

Scheinin NM, Scheinin M, Rinne JO.

Q J Nucl Med Mol Imaging. 2011 Jun;55(3):265-79. Review.

PMID:
21532540
9.

Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.

Folch J, Petrov D, Ettcheto M, Abad S, Sánchez-López E, García ML, Olloquequi J, Beas-Zarate C, Auladell C, Camins A.

Neural Plast. 2016;2016:8501693. doi: 10.1155/2016/8501693. Epub 2016 Jan 3. Review.

10.

Amylin Receptor: A Potential Therapeutic Target for Alzheimer's Disease.

Fu W, Patel A, Kimura R, Soudy R, Jhamandas JH.

Trends Mol Med. 2017 Aug;23(8):709-720. doi: 10.1016/j.molmed.2017.06.003. Epub 2017 Jul 7. Review.

PMID:
28694141
11.

Clusterin in Alzheimer's disease: a player in the biological behavior of amyloid-beta.

Li X, Ma Y, Wei X, Li Y, Wu H, Zhuang J, Zhao Z.

Neurosci Bull. 2014 Feb;30(1):162-8. doi: 10.1007/s12264-013-1391-2. Epub 2013 Dec 19. Review.

12.

Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease.

Clark IA, Vissel B.

Br J Pharmacol. 2015 Aug;172(15):3714-27. doi: 10.1111/bph.13181. Epub 2015 Jun 29. Review.

13.

Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease.

Bishop GM, Robinson SR.

Drugs Aging. 2004;21(10):621-30. Review.

PMID:
15287821
14.

PET and SPECT imaging in psychiatric disorders.

Zipursky RB, Meyer JH, Verhoeff NP.

Can J Psychiatry. 2007 Mar;52(3):146-57. Review.

PMID:
17479522

Supplemental Content

Support Center